此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

单臂、多中心研究评估为ATTR-CM患者配置的数字远程监控工具的可接受性和可行性:ACO-Monitor (ACO-MONITOR)

2026年11月19日 更新者:Bayer

一项观察性研究,旨在了解数字远程监测工具(Luscii)在转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)患者中的可接受性和实用性

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.

People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.

Remote monitoring offers a way for people living with ATTR-CM and their healthcare professionals to stay connected between clinic visits. Recent studies have shown that remote monitoring can help by making it easier to share health information, spot problems earlier, and support people to follow their treatment plans. This can lead to fewer hospital visits and better health outcomes.

Luscii is a digital remote monitoring tool designed to help people living with ATTR-CM and their healthcare professionals stay connected between clinic visits. Luscii has two main parts: Luscii contact, a smartphone app that allows secure messaging and video calls, and Luscii vitals, a clinical software system that organizes health data and can alert the healthcare team if there are changes that need attention. Luscii vitals is a CE-marked medical device used within its approved purpose and does not replace a doctor's judgement.

By making it easier to communicate and share information, Luscii aims to support earlier detection of problems, better management of ATTR-CM, and a more positive experience for people living with this condition.

The main purpose of this observational study, called ACO-MONITOR, is to learn how acceptable and practical Luscii is for people living with ATTR-CM and their healthcare professionals. The study will take place in Austria, Germany, and Italy at three specialist centers. About 60 adults with a diagnosis of hereditary or wild-type ATTR-CM will be invited to take part. There will be no treatments given as part of this study. Instead, participants will use the Luscii app and devices at home to track their health and share information with their healthcare professionals. The study team will provide training on how to use Luscii and will help participants get started.

The study team will look at:

  • How quickly and how often participants and healthcare professionals use Luscii
  • How long Luscii is used by each person
  • How many times participants use Luscii after being reminded
  • How easy Luscii is to use, based on questionnaires for both participants and healthcare professionals

The study will last about 18 months in total, including a 6-month period to invite participants and a 12-month follow-up period. During the study, the study team will:

  • Support participants in using Luscii to share health information from home
  • Monitor how often and how easily Luscii is used
  • Ask participants and healthcare professionals about their experiences using Luscii, including what worked well and what could be improved
  • Record any problems or technical issues with using Luscii By collecting this information, the researchers hope to learn if Luscii can help improve communication, support earlier detection of health problems, and make it easier for people living with ATTR-CM to manage their condition between clinic visits.

研究概览

地位

尚未招聘

条件

干预/治疗

研究类型

观察性的

注册 (估计的)

60

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Innsbruck、奥地利、6020
        • Medizinische Universität Innsbruck
      • Heidelberg、德国、69120
        • Universitätsklinikum Heidelberg
      • Pavia、意大利、27100
        • Policlinico San Matteo di Pavia

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Eligible participants will be invited by their treating physician and, after providing informed consent, will be observed for approx. 12 months. Patients with an established diagnosis of either wild-type or variant ATTR-CM can be enrolled. Evidence of assessment of all eligibility criteria by the physician or a delegate, as well as enrolment of a participant in the study should be documented in the participant medical records. Medical professionals who are directly involved in the participants' treatment and who have access to and will review the Luscii-captured data for routine care are asked to complete the study-specific questionnaires/forms.

描述

Inclusion Criteria:

For patients:

  • Adult (≥18 years at the date of signing the informed consent form (ICF)).
  • Diagnosis of either wild-type or variant ATTR-CM.
  • Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit.
  • Signed ICF.
  • Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application.

For medical professionals:

  • Directly involved in the treatment or clinical management of the enrolled ATTR-CM participants and having access to and reviewing the Luscii-captured data for routine care.
  • Agreement to ICF within the EDC system for the purpose of using Luscii or to complete the HCP Experience Questionnaire.

Exclusion Criteria:

For patients:

  • Participation in an investigational program with interventions outside of routine clinical practice.
  • Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.

For medical professionals:

  • Any current affiliation with Luscii, Bayer, or any of their affiliates.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Wild-type or variant ATTR-CM participants

Participants will be enrolled after the decision to initiate the use of the digital remote monitoring tool, Luscii, as per standard use.

The Luscii tool (CE class IIa certification) will be utilized for remote monitoring of health data specific to ATTR-CM patients. Following the observational nature of the study, no additional interventions will be implemented beyond the standard use of the Luscii tool. Participants will use the Luscii tool continuously throughout the observational period, which is approximately 12 months.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Acceptance of Luscii among medical professionals
大体时间:At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii vitals and Luscii contact throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Acceptance of Luscii among participants with ATTR-CM
大体时间:At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii contact throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for medical professionals
大体时间:At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of implementing the tool in real-world ATTR-CM care throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for participants with ATTR-CM
大体时间:At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of using the tool in real-world settings throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among participants
大体时间:At baseline (initial visit), at 6 months and at 12 months

Measured by the Patient Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among medical professionals
大体时间:At baseline (initial visit), at 6 months and at 12 months

Measured by the Healthcare Professional (HCP) Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months

次要结果测量

结果测量
措施说明
大体时间
筛选失败的受试者数量
大体时间:在基线(首次就诊)时
在基线(首次就诊)时
筛选失败的原因
大体时间:在基线(初次访视)
在基线(初次访视)
Participant demographic characteristics: age
大体时间:At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline (initial visit)

At baseline (initial visit)
Participant demographic characteristics: sex
大体时间:At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Participant demographic characteristics: race
大体时间:At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Clinical characteristics: National Amyloidosis Centre (NAC) Stage
大体时间:At baseline (initial visit)

Categorization of participants according to the NAC Stage into stages I, II, or III, with stage III indicating a higher risk of mortality

At baseline (initial visit)
Clinical characteristics: relevant comorbidities
大体时间:At baseline (initial visit)

ATTR-CM relevant comorbidities

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM prior medications
大体时间:At baseline (initial visit)

Concomitant medications administered within the past 12 months before initial visit

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM concomitant medications
大体时间:At baseline (initial visit)

Previously administered ATTR-CM related medications within the past 12 months before initial visit

At baseline (initial visit)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月30日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年6月30日

研究注册日期

首次提交

2026年4月23日

首先提交符合 QC 标准的

2026年4月23日

首次发布 (实际的)

2026年4月29日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月19日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 23127

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.